Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma

NCT03988647 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Business decision

Conditions

Merkel Cell Carcinoma

Interventions

DRUG: Pembrolizumab
RADIATION: Radiation Therapy

Sponsor

Stanford University